AstraZeneca (LON:AZN) has been given a GBX 7,900 ($103.23) price objective by stock analysts at JPMorgan Chase & Co. in a research note issued to investors on Wednesday, Borsen Zeitung reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 7.15% from the company’s previous close.
Several other analysts have also recently issued reports on the company. Bryan, Garnier & Co restated a “neutral” rating on shares of AstraZeneca in a research note on Wednesday, July 3rd. Deutsche Bank restated a “buy” rating and set a GBX 6,900 ($90.16) price objective on shares of AstraZeneca in a research note on Friday, July 26th. Jefferies Financial Group cut their price objective on AstraZeneca from GBX 6,400 ($83.63) to GBX 6,350 ($82.97) and set a “hold” rating on the stock in a research note on Friday, May 24th. Citigroup restated a “buy” rating and set a GBX 7,000 ($91.47) price objective on shares of AstraZeneca in a research note on Monday, May 13th. Finally, Barclays upped their price objective on AstraZeneca from GBX 7,600 ($99.31) to GBX 7,800 ($101.92) and gave the company an “overweight” rating in a research note on Friday, August 16th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of GBX 6,688.24 ($87.39).
Shares of LON AZN opened at GBX 7,373 ($96.34) on Wednesday. The stock’s 50 day moving average price is GBX 6,870.36 and its two-hundred day moving average price is GBX 6,274.74. AstraZeneca has a 52-week low of GBX 5,312 ($69.41) and a 52-week high of GBX 7,475.15 ($97.68). The stock has a market capitalization of $96.08 billion and a P/E ratio of 43.07. The company has a quick ratio of 0.74, a current ratio of 0.95 and a debt-to-equity ratio of 144.48.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Story: Economic Bubble
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.